HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.

Abstract
Nuclear factor (NF)-YB, a subunit of the transcription factor nuclear factor Y (NF-Y) complex, binds and activates CCAAT-containing promoters. Our previous work suggested that NF-YB may be a mediator of topoisomerase IIα (Top2α), working through the Top2α promoter. DNA topoisomerase II (Top2) is an essential nuclear enzyme and the primary target for several clinically important anticancer drugs. Our teniposide-resistant human lymphoblastic leukemia CEM cells (CEM/VM-1-5) express reduced Top2α protein compared with parental CEM cells. To study the regulation of Top2α during the development of drug resistance, we found that NF-YB protein expression is increased in CEM/VM-1-5 cells compared with parental CEM cells. This further suggests that increased NF-YB may be a negative regulator of Top2α in CEM/VM-1-5 cells. We asked what causes the up-regulation of NF-YB in CEM/VM-1-5 cells. We found by microRNA profiling that hsa-miR-485-3p is lower in CEM/VM-1-5 cells compared with CEM cells. MicroRNA target prediction programs revealed that the 3'-untranslated region (3'-UTR) of NF-YB harbors a putative hsa-miR-485-3p binding site. We thus hypothesized that hsa-miR-485-3p mediates drug responsiveness by decreasing NF-YB expression, which in turn negatively regulates Top2α expression. To test this, we overexpressed miR-485-3p in CEM/VM-1-5 cells and found that this led to reduced expression of NF-YB, a corresponding up-regulation of Top2α, and increased sensitivity to the Top2 inhibitors. Results in CEM cells were replicated in drug-sensitive and -resistant human rhabdomyosarcoma Rh30 cells, suggesting that our findings represent a general phenomenon. Ours is the first study to show that miR-485-3p mediates Top2α down-regulation in part by altered regulation of NF-YB.
AuthorsCheng-Fen Chen, Xiaolong He, Ahmet Dirim Arslan, Yin-Yuan Mo, William C Reinhold, Yves Pommier, William T Beck
JournalMolecular pharmacology (Mol Pharmacol) Vol. 79 Issue 4 Pg. 735-41 (Apr 2011) ISSN: 1521-0111 [Electronic] United States
PMID21252292 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CCAAT-Binding Factor
  • DNA-Binding Proteins
  • MIRN483 microRNA, human
  • MicroRNAs
  • Poly-ADP-Ribose Binding Proteins
  • nuclear factor Y
  • Etoposide
  • Teniposide
  • DNA Topoisomerases, Type II
  • TOP2A protein, human
Topics
  • Antigens, Neoplasm (biosynthesis, genetics)
  • Antineoplastic Agents (toxicity)
  • CCAAT-Binding Factor (metabolism)
  • Cell Line, Tumor
  • DNA Topoisomerases, Type II (biosynthesis, genetics)
  • DNA-Binding Proteins (antagonists & inhibitors, biosynthesis, genetics)
  • Down-Regulation (drug effects)
  • Drug Resistance, Neoplasm
  • Etoposide (toxicity)
  • Gene Expression Regulation, Enzymologic (drug effects, physiology)
  • Humans
  • MicroRNAs (physiology)
  • Poly-ADP-Ribose Binding Proteins
  • Teniposide (toxicity)
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: